Mobile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs and...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-010739-42

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of tadalafil 5 mg once daily for 12 weeks compared with placebo in improving the IPSS in men with signs and symptoms of BPH, also referred to as BPH-LUTS (lower urinary tract symptoms).

Critère d'inclusion

  • benign prostatic hyperplasia (BPH)

Liens